Eli Lilly wins oral obesity pill approval and signs sleep deal
The approval gives Lilly a pill option against Novo Nordisk's oral semaglutide, while a separate sleep transaction broadens the company's pipeline.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 5 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly secured approval for its oral obesity drug and announced a sleep-focused deal, moves the report frames as reshaping the company's growth outlook.
- 02An approved oral incretin changes prescribing and dispensing logistics for clinics and pharmacies that have relied on injectables.
- 03Launch pricing, payer coverage and supply volumes will determine real-world access; the report does not detail those terms.
From the source
Read at finance.yahoo.comEli Lilly Obesity Pill Approval And Sleep Deal Reshape Growth Story
